Six Months Results of the Duodenal-Jejunal Bypass Liner for the Treatment of Obesity and Type 2 Diabetes
|Eduardo Guimarães Hourneaux De Moura1*, Bruno Da Costa Martins1, Guilherme Sauniti Lopes1, Ivan Roberto Bonotto Orso1, Suzana Lopes De Oliveira1, Marcio C. Mancini1, Manoel Passos Galvão Neto2, Marco Aurélio Santo3, Paulo Sakai1 and Ivan Cecconello3|
|1Department of Gastroenterology, Gastrointestinal Endoscopy Unit, University of São Paulo Medical School, São Paulo, Brazil|
|2Department of Gastro Obeso Center, University of São Paulo Medical School, São Paulo, Brazil|
|3Department of Gastroenterology - University of São Paulo Medical School, São Paulo, Brazil|
|Corresponding Author :||Eduardo Guimarães Hourneaux de Moura
Av. Dr. Enéas de Carvalho Aguiar
255, Ambulatory Building - 6th floor
Endoscopy Unit, 05403-900, São Paulo, Brazil
|Received October 17, 2011; Accepted April 17, 2012; Published April 19, 2012|
|Citation: De Moura EGH, Martins BDC, Lopes GS, Orso IRB, De Oliveira SL, et al. (2012) Six Months Results of the Duodenal-Jejunal Bypass Liner for the Treatment of Obesity and Type 2 Diabetes. J Gastrointest Dig Syst S2:003. doi: 10.4172/2161-069X.S2-003|
|Copyright: © 2012 De Moura EGH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device that excludes the duodenum and initial portion of the jejunum from the contact with the chyme. It has been shown to be effective for weight loss and may improve the control of type 2 diabetes mellitus (T2DM). The objective of this study is to evaluate the efficacy of the DJBL in weight loss and in T2DM control over a 24-week period.
Patients and Methods: Obese (BMI ≥ 35 kg/m²) and T2DM patient candidates for bariatric surgery were prospectively assigned to the implant of the DJBL at an academic endoscopy referral center (São Paulo - Brazil) Results: Twenty-two patients were submitted to the implant procedure, with technical success of 100%. At week 24, mean weight loss was 14 kg (p<0.001). BMI dropped on average 5.4 points and excess weight loss was 22.2%. Fasting glucose (baseline = 171.8 mg/dl; W24 = 141.5 mg/dl) and glycosylated hemoglobin levels (8.8% to 7.3%) were significantly reduced. There was also a reduction in the usage of anti-diabetic medications (except metformin).
Conclusions: The DJBL is an effective weight loss method and also promotes glucose control over a 24-week period. Long-term studies with post-removal follow-up are required to determine its role in the management of type 2 diabetes.